Although the strong PARP trapper talazoparib has shown to sensitize GBM cell lines and orthotropic GBM models to TMZ, it has demonstrated a restricted ability to cross the BBB.44 A phase II trial of talazoparib is currently recruiting recurrent high-grade glioma patients with DDR deficiency to investigate if combining carboplatin and radiation may sensitize tumors to PARP inhibition and increase talazoparib drug penetration across the BBB (NCT04740190). This evidence concerns the gene PARP1 and central nervous system cancer.